OTCM
AXRX
Market cap33kUSD
May 12, Last price
0.00USD
Name
Amexdrug Corp
Chart & Performance
P/E
0.84
P/S
0.01
EPS
0.00
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-17.77%
Revenues
3m
-14.61%
Net income
40k
+252.18%
CFO
27k
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Amexdrug Corporation, founded in 1963 and headquartered in Commerce, California, operates as a pharmaceutical and cosmeceutical enterprise. Primarily, the company, via its subsidiaries, distributes pharmaceutical products. Beyond this core function, Amexdrug is also deeply involved in the entire lifecycle of pharmaceutical drugs, cosmetics, and medical devices, from their research and development phases through manufacturing and ultimate sale. The company's operations are divided into two main divisions: Distribution and Health and Beauty Products. Its extensive distribution network encompasses a wide range of items, including prescription and over-the-counter medications, various non-drug products, and health and beauty essentials. Amexdrug also provides services in private manufacturing and labeling. Specific product lines manufactured and sold by the company, often under its Sponix brand, include facial and body creams, arthritic pain relief treatments, and hair and nail care products. These goods are supplied to a diverse clientele such as pharmacies, beauty salons, beauty supply outlets, and other retail establishments. Within the state of California, Amexdrug's distribution channels primarily target independent pharmacies, extending secondarily to smaller pharmacy chains, alternative care facilities, and various wholesalers and retailers. The company adopted the name Amexdrug Corporation in April 2000, changing from its previous identity as Harlyn Products, Inc., to reflect its strategic focus on pharmaceutical sales.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||